Please wait while we load the requested 10-Q report or click the link below:
FISCAL 2006 THIRD QUARTER FINANCIAL RESULTS
|||Net sales increased 29% to $76.0 million.|
|||Pretax income increased 13% to $27.6 million.|
|||Income per diluted share increased to $0.46, including a one-time pretax charge of $1.5 million or $0.03 per diluted share recorded in connection with moving the corporate headquarters.|
|||Mucinex® franchise gained nearly 4 market share points during the 2005-2006 cough/cold season and became the No. 2 product in the cough/cold/allergy/sinus category, according to Information Resources Inc. (IRI) weekly consumption data thru Mar. 19, 2006, and monthly brand data for the 12-weeks ended Mar. 19, 2006.|
|||Launched a new advertising campaign for Mucinex® D on Feb. 23, targeting sufferers of congested allergies. Initial consumer response to Mucinex® D is encouraging.|
|||Commenced Phase IIb clinical program for erdosteine in late March.|
|||Made solid progress in manufacturing and increased production.|
|||Relocated Adams corporate headquarters in April 2006 to a larger facility in Chester, N.J.|
|||Initiated plans for a sales force expansion to be completed in July 2007.|
The following information was filed by Adams Respiratory Therapeutics, Inc. on Thursday, May 11, 2006 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Adams Respiratory Therapeutics, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Adams Respiratory Therapeutics, Inc..